Trial · NCT07902934
Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke
NCT07902934, Not applicable, Not yet recruiting, Tri-Service General Hospital (TSGH)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke. Trials, record NCT07902934. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902934
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke
- NCT number
- NCT07902934
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Tri-Service General Hospital (TSGH)
- Conditions
- Acute Ischemic Stroke
- Interventions
- NRICM301, Matching Placebo
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Study Product-Related Treatment-Emergent Adverse Events | From the first dose on Day 1 through Day 15 | The percentage of participants with at least one treatment-emergent adverse event (TEAE) assessed as possibly, probably, or definitely related to the study product will be compared between groups. A TEAE is an event that starts after the first dose or a pre-existing symptom, disease, or laboratory abnormality that worsens after the first dose. Relatedness is assessed by the study physician. The safety population includes randomized participants who receive at least one dose, analyzed according to actual treatment received. |
| Secondary | From the first dose on Day 1 through Day 15 | From the first dose on Day 1 through Day 15 | The percentage of participants with at least one TEAE, regardless of relatedness to study product, will be compared between groups. TEAEs include new events after the first dose and worsening of pre-existing conditions or laboratory abnormalities after the first dose. |
| Secondary | Percentage of Participants With Serious Adverse Events Through Day 15 | From the first dose on Day 1 through Day 15 | The percentage of participants with at least one serious adverse event will be compared between groups. Serious events include death, life-threatening events, hospitalization or prolonged hospitalization, persistent disability, congenital anomalies, or other medically important events. |
| Secondary | Percentage of Participants With Adverse Reactions Through Day 15 | From the first dose on Day 1 through Day 15 | The percentage of participants with at least one adverse reaction assessed as possibly, probably, or definitely related to study product will be compared between groups. Relatedness will be assessed by the study physician. |
| Secondary | Percentage of Participants With Hemorrhagic Transformation Through Day 15 | From the first dose on Day 1 through Day 15 | The percentage of participants with hemorrhagic transformation of the ischemic stroke will be compared between groups. Imaging confirmation and hemorrhage classification will be recorded, including hemorrhagic infarction and parenchymal hematoma categories, with symptomatic status recorded. |
| Secondary | Percentage of Participants With Adverse Events Through Day 91 | From the first dose on Day 1 through Day 91 (final visit window: +/- 7 days) | The number and percentage of participants with at least one adverse event, regardless of its relationship to the study product will be summarized by group. Event timing, severity, relatedness, and outcomes will be recorded as applicable. Exploratory between-group comparisons may be performed. |
| Secondary | Percentage of Participants With Serious Adverse Events Through Day 91 | From the first dose on Day 1 through Day 91 (final visit window: +/- 7 days) | The number and percentage of participants with at least one serious adverse event, regardless of its relationship to the study product will be summarized by group. Event timing, severity, relatedness, and outcomes will be recorded as applicable. Exploratory between-group comparisons may be performed. |
| Secondary | Percentage of Participants With Death Through Day 91 | From the first dose on Day 1 through Day 91 (final visit window: +/- 7 days) | The number and percentage of participants with death from any cause will be summarized by group. Event timing, severity, relatedness, and outcomes will be recorded as applicable. Exploratory between-group comparisons may be performed. |
| Secondary | Percentage of Participants With Recurrent Stroke Through Day 91 | From the first dose on Day 1 through Day 91 (final visit window: +/- 7 days) | The number and percentage of participants with a recurrent stroke event will be summarized by group. Event timing, severity, relatedness, and outcomes will be recorded as applicable. Exploratory between-group comparisons may be performed. |
| Secondary | Percentage of Participants With Hemorrhagic Transformation Through Day 91 | From the first dose on Day 1 through Day 91 (final visit window: +/- 7 days) | The number and percentage of participants with hemorrhagic transformation of the ischemic stroke, documented with imaging findings will be summarized by group. Event timing, severity, relatedness, and outcomes will be recorded as applicable. Exploratory between-group comparisons may be performed. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902934
GET https://conductscience.org/api/trials/v1/NCT07902934/registered